论文部分内容阅读
目的:观察巴曲酶联合立普妥治疗急性脑梗死的临床疗效。方法:急性脑梗死患者124例随机分为对照组31例,立普妥组31例,巴曲酶组31例,联合组31例。对照组给予抗血小板凝集、脱水、降颅压等常规治疗;立普妥组在常规治疗基础上给予立普妥20mg,1次/d,每晚口服,疗程1~2个月;巴曲酶组在常规治疗基础上给予巴曲酶,首次剂量10 BU,并于治疗第3天,第5天分别用5 BU,均以生理盐水100 mL稀释后,静脉滴注,1次/d,30 min内滴完;联合组立普妥用法同立普妥组,巴曲酶用法同巴曲酶组。4组疗程均为20 d。比较4组治疗前、治疗后7,15,20 d神经功能缺损评分、日常生活活动量表评分及不良反应。结果:4组治疗15,20 d后神经功能缺损评分均较治疗前降低(P<0.05);联合组治疗7,15,20 d后神经功能缺损评分均低于对照组(P<0.05),治疗20 d后神经功能缺损评分低于巴曲酶组和立普妥组(P<0.05)。4组治疗20 d后日常生活活动量表评分均高于治疗前(P<0.05),联合组高于巴曲酶组、立普妥组、对照组(P<0.05)。4组不良反应发生率比较差异无统计学意义(P>0.05)。结论:立普妥联合巴曲酶可提高急性脑梗死疗效,且不增加不良反应发生率。
Objective: To observe the clinical efficacy of batroxobin combined with Lipitor in the treatment of acute cerebral infarction. Methods: 124 patients with acute cerebral infarction were randomly divided into control group (31 cases), Lipitor (31 cases), batroxobin (31 cases) and combination group (31 cases). Control group was given antiplatelet aggregation, dehydration, intracranial pressure and other conventional treatment; Lipitor group on the basis of conventional treatment given Lipitor 20mg, 1 / d, every night oral treatment for 1 to 2 months; batroxobin Batroxobin was administrated on the basis of routine treatment. The first dose of 10 BU was given. On the third day and the fifth day of treatment, the rabbits were given 5 BU respectively. After diluting with 100 mL of normal saline, intravenous drip, once per day, 30 d min drip finished; combination group Lipitor use with Lipitor group, batroxobin usage with batroxobin group. Four groups of treatment were 20 d. The scores of neurological deficits, daily living scale scores and adverse reactions on the 7th, 15th and 20th day after treatment in the 4 groups were compared. Results: The scores of neurological deficit in the four groups after treatment for 15 and 20 days were lower than those before treatment (P <0.05). The scores of neurological deficits in the combined group after 7, 15 and 20 days were lower than those in the control group (P <0.05) After 20 days of treatment, the score of neurological deficit was lower than that of batroxobin and Lipitor group (P <0.05). The score of activity scale of daily living in the four groups after treatment for 20 days was higher than that before treatment (P <0.05), and the combined group was higher than batroxobin, Lipitor group and control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the four groups (P> 0.05). Conclusion: Lipitor combined with batroxobin can improve the efficacy of acute cerebral infarction without increasing the incidence of adverse reactions.